Advice
following a full submission
rosuvastatin (Crestor®) is not recommended for use within NHS Scotland.
Indication under review: Prevention of major cardiovascular events in patients who are estimated to have a high risk for a first cardiovascular event as an adjunct to correction of other risk factors.
In a randomised, placebo-controlled, double-blind, multi-centre study, treatment with rosuvastatin was associated with a significantly reduced risk of first cardiovascular event versus placebo in patient sub-groups deemed to be high-risk when assessed using the Framingham equation and the SCORE algorithm.
The submitting company did not present sufficiently robust economic analysis to gain acceptance by SMC.
Download detailed advice283KB (PDF)
Medicine details
- Medicine name:
- rosuvastatin (Crestor)
- SMC ID:
- 725/11
- Indication:
- For the prevention of major cardiovascular events in patients estimated to have a high risk for a first cardiovascular event.
- Pharmaceutical company
- AstraZeneca UK Ltd
- BNF chapter
- Cardiovascular system
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 10 October 2011